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Background:  We hypothesized that therapy with the angiotensin II type 1 receptor blocker candesartan (CN), by reducing effects of increased 
angiotensin II, modulates healing-specific matricellular proteins such as secretory leucocyte protease inhibitor (SLPI), secreted protein acidic and 
rich in cysteine (SPARC) and osteopontin (OPN) as well as other matrix metalloproteases (MMPs) and cytokines during healing after reperfused 
myocardial infarction (RMI) and thereby limits left ventricular (LV) remodeling and dysfunction.
Methods:  We randomized 60 young (3 months) and 60 adult (12 months) Sprague-Dawley rats 24 h after RMI (1-h left anterior descending 
coronary occlusion; reperfusion) to 3 weeks of oral placebo and CN (30 mg/kg). Sham rats had no RMI or drug. We measured serial LV function and 
remodeling (echocardiography/Doppler), and infarct-scar size at 3 weeks.
Results:  Compared to sham, RMI-placebo induced more infarct-scar mass (as % risk), LV dysfunction and remodeling in older than young rat 
hearts. Compared to placebo, CN limited LV systolic and diastolic dysfunction and remodeling (LV volume/mass ratios) in both groups. Compared to 
non-infarct zones, RMI induced robust increases (P<0.001) in angiotensin II, SLPI, SPARC and OPN proteins and mRNAs, MMP-9 and MMP-2 (activity 
and protein), and inducible-nitric-oxide-synthase (iNOS), interleukin (IL)-6, tumor necrosis factor (TNF)-_, transforming growth factor (TGF)-`1, 
Smad-2 and myelopeoxidase proteins in the ischemic zones. Importantly, these increases were all greater (P<0.01) in the older hearts and CN 
attenuated all the changes. 
Conclusions:  CN attenuates aging-induced increases in angiotensin II, matricellular proteins and matrix proteases, cytokines, and myelopeoxidase 
thereby limiting adverse LV remodeling and dysfunction during healing after RMI.
